For laboratory research use only - not for human consumption

Thematic hub

Are peptides legal in Australia? Research peptide schedule status

Whether a peptide is legal in Australia depends on the compound, the product and what you do with it. Some uses need a prescription, an approval or an authority. BPC-157, CJC-1295, ipamorelin and TB-500 have named Schedule 4 and Appendix D entries in the October 2026 Poisons Standard. We read the as-made text on 14 October 2026. The TGA says a research-use-only label does not remove legal duties. We read its guidance on 14 October 2026. This page does not present research material as approved for personal human use.

Articles 4Updated 2026-10-14Written by Form Laboratories research team

We read two TGA pages on 14 October 2026 for this update. One is the TGA peptide products page (last updated 23 September 2026). The other is the TGA's explanation of how it regulates therapeutic peptide products. Jump to the per-compound schedule table. It records the October 2026 Poisons Standard. The as-made text is dated 28 September 2026. It is in force from 1 October 2026. It also shows the date we read each entry: 14 October 2026.

Most readers start with one question: is this peptide legal in Australia? The Poisons Standard sorts substances through named entries and wider group entries. New editions of the list replace old ones. So every statement about it needs a date.

This page reads that list against one catalogue. For each compound, it says what the October 2026 edition says. It quotes the entry text and gives the day we read it. It then answers the import and sport questions from the regulators' own pages. It is not legal advice. It never says what any person may lawfully do. Western Australia adds its own rules, set out on the WA law page.

Key facts

Key facts for Are peptides legal in Australia? Research peptide schedule status
Document readTherapeutic Goods (Poisons Standard, October 2026) Instrument 2026
Register IDF2026L01327 (Federal Register of Legislation)
Also cited asStandard for the Uniform Scheduling of Medicines and Poisons No. 51 (section 1(2))
Dated28 September 2026
In force from1 October 2026 (commencement table)
ReplacesThe June 2026 edition, repealed by section 4(1)
Date read14 October 2026, world time (UTC), as-made text on legislation.gov.au
Catalogue compounds in the table12
Held, no status statedGHK-Cu and tesamorelin
Not coveredLater editions and blended products
Other regulator pages readTGA, FDA, Sport Integrity Australia and Australia Post pages, read 14 October 2026
TGA, Peptide products, last updated 23 September 2026TGA advisory, 13 April 2026TGA and Chief Medical Officer joint statement, 19 June 2026

Are peptides illegal in Australia, and why?

No. In the regulator's own account, peptides as a class are not illegal. The TGA says some peptide products are approved for use in Australia. It also says many products sold online are unapproved therapeutic goods. They 'may be unlawful to import, supply or advertise'. Source: TGA, Peptide products, last updated 23 September 2026. The TGA gives a reason. It has not assessed these products for safety, quality or effectiveness. So there is 'no assurance they are safe, effective, correctly labelled, sterile or made to appropriate quality standards'. Named entries in the Poisons Standard add separate controls.

The TGA lists what is not known about these products. These are how they are made, whether they are sterile, how they work in the body, what side effects they may cause and what they contain. Source: TGA advisory, 13 April 2026. The advisory lists problems reported to the TGA. These include severe allergic reactions that needed adrenaline and a hospital stay. They also include a body-wide inflammatory response that needed hospital care. They also include muscle and tendon injuries such as plantar fasciitis and Achilles tendinitis. These are reports to a regulator, not rates. Source: TGA advisory, 13 April 2026.

Professor Michael Kidd is the Chief Medical Officer. He is quoted in the joint TGA and Chief Medical Officer statement of 19 June 2026. He said, 'Some of these products have not undergone sufficient human clinical trials and may cause significant harm.' That is a health warning. The legal rules are in the Schedule 4, Appendix D, import and possession sections of this page.

Federal Register of Legislation, F2026L01327, sections 4 and 7 and the reader's guide

Evidence limits

What can this page not tell you?

This page records one reading of one document on one date. It gives no verdict on any person's situation. The Federal Register of Legislation supplied F2026L01327, the October 2026 Poisons Standard, dated 28 September 2026. We read the as-made text on 14 October 2026, in world time (UTC). A later edition may differ. This page does not cover one. GHK-Cu and tesamorelin are held, so the page states no status for either. Blended products are not covered.

An instrument is the legal document that holds the list. An edition is one dated version of it.

The instrument's own reader's guide says a poison in a Schedule shows the degree of control needed if it is marketed. It does not show that the poison is available or approved. It also does not remove any duty to register therapeutic goods. So a Schedule entry is a sorting label, not a permission. A missing entry is not a permission either. Section 7 of the instrument says that, unless the contrary intention appears, a reference to a substance includes 'every salt, active principle or derivative of the substance'. It also includes 'a preparation or admixture containing any proportion of the substance'. A derivative is a substance made by changing the original. So a named entry can reach more than the exact name. A missing name also does not settle what the group headings (class entries) cover.

New editions replace old ones. Section 4(1) of the October 2026 instrument repeals the June 2026 edition. Read this page again for each new edition. The read date in the table shows which edition we last checked.

Federal Register of Legislation, F2026L01327, Schedule 4Catalogue record of this site

Which research peptides are in Schedule 4?

Schedule 4 is headed 'Prescription only medicines and prescription animal remedies'. It holds BPC-157, CJC-1295 (named with CAS No. 863288-34-0), ipamorelin, TB-500 and tirzepatide as named entries in F2026L01327, the October 2026 instrument. We read the as-made text on 14 October 2026, UTC. A CAS number is a registry number that names one chemical. The first four entries carry a # marker. The instrument's note explains it as 'Substances marked # are listed in Appendix D'. These four also appear in Appendix D. Tirzepatide does not.

For the other seven catalogue compounds, this page states no Schedule 4 status. For five of them we found no individual entry. The other two are held.

The table below quotes each entry text. The instrument's spaced hyphens are written as ordinary hyphens. The research guides put each compound in context: BPC-157, CJC-1295 with ipamorelin and TB-500.

This site's catalogue lists a product named 'CJC-1295 (No DAC) & Ipamorelin'. The instrument names CJC-1295 with the CAS number above. It does not use the label 'No DAC'. So this page does not decide whether that form falls under the named entry.

  • SourceF2026L01327Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026
  • GuideBPC-157A plain-English guide to BPC-157: what it is, the tissue-repair research (in cells and animals), and where the human evidence stands.
  • GuideCJC-1295 with ipamorelinA plain-English guide to CJC-1295 (No DAC), Ipamorelin, the with DAC caveat, and the compliance limits around this research set.
  • GuideTB-500A plain-English guide to TB-500: the actin-binding fragment of thymosin beta-4, what's been studied, and why it isn't the same as the full protein.
Federal Register of Legislation, F2026L01327, Appendices D, F and LTGA advisory, 13 April 2026

What is Appendix D in the Poisons Standard?

Appendix D is a set of tables placed after the schedules in the Poisons Standard. Clause 5 is a numbered part of it, headed 'Poisons for which possession without authority is illegal'. In the instrument's words, it 'specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)'. An appendix is a table or list placed after the schedules.

We read the as-made text of F2026L01327, the October edition, on 14 October 2026 (UTC). The clause 5 table has 41 items. It puts BPC-157 at item 5, CJC-1295 at item 7, ipamorelin at item 25 and TB-500 at item 38.

Item numbers can change between editions while an entry stays. So the table names the item and the edition together.

State and territory laws may add controls on possession (TGA advisory, 13 April 2026). So the instrument alone does not settle any person's position. This page does not try to.

Tirzepatide follows a different path. Its Schedule 4 entry has no # marker, so it has no Appendix D entry. It appears in Appendix L, clause 2 ('Additional warning statements for certain human medicines'), item 41. That item points to warning statement number 67 in Appendix F, clause 1. We do not copy the warning text here.

Federal Register of Legislation, F2026L01327, section 64 and Appendix DTGA advisory, 13 April 2026TGA and Chief Medical Officer joint statement, 19 June 2026

Is it illegal to possess peptides in Australia?

Possession is controlled by substance, not by the word 'peptide'. Section 64(4) of the October 2026 Poisons Standard says this about a poison in the table in clause 5 of Appendix D. It 'must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs'. Source: F2026L01327, as-made text read 14 October 2026. That table names BPC-157, CJC-1295, ipamorelin, TB-500 and AOD-9604 among its 41 items. For other peptides, state and territory laws may add controls on possession. Source: TGA advisory, 13 April 2026.

The clause 5 table also holds group entries. Items 15, 16, 18, 19, 21 and 24 name these groups. They are fibroblast growth factors, follistatin, growth hormone releasing hormones, growth hormone releasing peptides, growth hormone secretagogues and insulin-like growth factors. Item 39 names thymosin beta 4. Items 18, 19 and 21 add 'including those separately specified in Schedule 4'. We read this on 14 October 2026.

'Authority' is the instrument's own word. Its example is a legal prescription (Appendix D, clause 5). The regulator pages we read do not say whether a given person may lawfully use a peptide. This page does not say it either. The 19 June 2026 joint statement from the TGA and the Chief Medical Officer is a health warning about unapproved peptide products. It is not a legal ruling.

Federal Register of Legislation, F2026L01327Nature Reviews Molecular Cell Biology 2021

What does 'no individual entry' mean?

It means we searched the text of the as-made October instrument F2026L01327 on 14 October 2026 (UTC). We found no named entry. The search covered semax, selank, NAD+, MOTS-c and retatrutide. We used each name plus variant spellings, spelled-out names and research codes (lab identifiers) where they exist. This does not mean any of them is lawful, approved, free to possess or free to sell.

It also does not show that no group heading applies, because section 7 reaches derivatives and preparations. Scheduling status and TGA approval are separate questions.

NAD+ is short for nicotinamide adenine dinucleotide. It is a coenzyme, a helper molecule for enzymes. Source: Covarrubias et al., 2021, a review article. NAD+ is built from small chemical units called nucleotides. It is not built from a chain of amino acids. Source: ChEBI, CHEBI:15846. The instrument text we read has no entry under either name.

TGA advisory, 13 April 2026TGA warning, 7 May 2026TGA, Personal Importation Scheme, last updated 8 September 2026

Can you import peptides into Australia?

Only if the import meets strict conditions. The TGA says a 'research use only' disclaimer does not permit importation. Source: TGA advisory, 13 April 2026. The Personal Importation Scheme is the TGA scheme for people who import goods for themselves or their immediate family. An import is covered only if it meets all of the scheme's conditions. Source: TGA, last updated 8 September 2026, read 14 October 2026.

The conditions include a valid Australian prescription or written authority when the medicine is prescription-only in Australia. The product must also be in its original packaging, or in packaging that lets it be identified accurately. Source: TGA, Personal Importation Scheme, last updated 8 September 2026. The TGA warning of 7 May 2026 says poorly labelled vials will not be released under the scheme.

The scheme covers goods for the importer's own use or for their immediate family. The goods 'cannot be sold or supplied to any other person'. Source: TGA, Personal Importation Scheme. The TGA says it will tell Australian Border Force (ABF) to seize and destroy peptide products at the border. This is when they fail the rules because of poor labelling. Source: TGA, 7 May 2026.

We do not test any compound against these conditions here. A parcel posted between two Australian addresses is not an import. The Perth ordering page covers that side. State and territory laws may still add controls.

We record these conditions as facts from the regulator. We do not assess any planned personal import.

Australia Post, Prohibited and Restricted Items List and Packaging Guide, 22 May 2024TGA advisory, 13 April 2026TGA warning, 7 May 2026TGA, Entering Australia, last updated 27 March 2024

Is it illegal to mail peptides, or to bring them into Australia?

Australia Post's Prohibited and Restricted Items List and Packaging Guide lists 'any poison listed in the Commonwealth Standard for Uniform Scheduling of Drugs & Poisons' among toxic substances. The guide is the 22 May 2024 edition. We read it on 14 October 2026. This page takes that to mean the Poisons Standard. There is an exception for therapeutic drugs and medicines, ready for use. They can be carried under the conditions in its Restricted Items List. These include that carriage will not cause a breach of any State, Territory or Commonwealth law. For goods from overseas, the TGA says a 'research use only' disclaimer does not permit importation. Goods that fail the Personal Importation Scheme conditions may be seized and destroyed. Sources: TGA advisory, 13 April 2026, and TGA warning, 7 May 2026.

For a scheduled medicine sent under those conditions, the guide's domestic rules add two points. A qualified medical practitioner, dentist, pharmacist or veterinarian must have prescribed the item for therapeutic purposes. The addressee must be such a practitioner, a hospital or medical clinic, or the person the substance was prescribed for. The guide names no peptides. Whether a given peptide is a scheduled poison depends on the Poisons Standard entries read in the sections above.

People who bring goods in by hand have a separate route. The TGA's Entering Australia page describes the traveller's exemption. It was last updated on 27 March 2024. We read it on 14 October 2026. It covers some medicines for personal use, or for an immediate family member who travels with the person. The product must stay in its original packaging. Prescription medicines need a prescription or a doctor's letter. The supply can be no more than 3 months. The list of covered categories includes medicines that lower blood glucose. It does not name research peptides.

The import section above links to the TGA's full Personal Importation Scheme requirements.

Sport Integrity Australia, 13 May 2026Sport Integrity Australia, Peptides explained, read 14 October 2026

Are peptides banned in sport in Australia?

Many peptides are banned in sport under the World Anti-Doping Code. That is the international anti-doping rulebook. Sport Integrity Australia (SIA) says so in its statement of 13 May 2026. SIA lists BPC-157, CJC-1295, ibutamoren (MK-677), ipamorelin, MOTS-c and thymosin beta-4 (TB-500) as common examples. Source: SIA, Peptides explained, page read 14 October 2026. Under Australia's strict-liability rules, athletes are responsible for any banned substance in their body, whatever the source. Source: SIA, 13 May 2026. These are sport rules. They are separate from the Poisons Standard.

A Therapeutic Use Exemption (TUE) is an approval. It can let an athlete use a banned medicine that a doctor prescribes. SIA says a TUE is 'unlikely to be granted for an unregistered medicine'. The athlete may then face an anti-doping rule violation (ADRV). Source: SIA, Peptides explained. SIA points athletes to the Global DRO website. It shows the status of substances on the World Anti-Doping Agency (WADA) Prohibited List. SIA also points to the Sport Integrity App.

This page makes no sport statement about any compound that those SIA pages do not name.

FDA, Category 2 bulk drug substances page, 22 April 2026FDA, 503A bulk drug substances page, 14 May 2026FDA advisory committee page, 23-24 July 2026FDA warning letter 733652, 24 August 2026

What peptides has the FDA banned?

The FDA pages we read publish no ban on peptides as a class. Its compounding rules sort some bulk drug substances into categories. Category 2 lists substances that may carry significant safety risks. Source: FDA, page current as of 22 April 2026, read 14 October 2026. That list names the peptides GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. BPC-157, CJC-1295, TB-500 and 14 other substances sit on a separate list on the same page. Those are substances that were nominated and then withdrawn by the people who nominated them. These lists are about compounding. That is separate from FDA approval of a drug.

The FDA's wording is about compounding, where a pharmacy makes up a medicine for one patient. Under section 503A, state-licensed pharmacists and doctors may compound only with bulk substances that meet one of three tests. The substance must have a pharmacopoeia monograph. Or it must be part of an FDA-approved drug. Or it must be on the 503A bulks list. For category 2 substances the FDA says it 'would consider taking action against a compounder'. This is under its general enforcement policies. Source: FDA, 503A bulk drug substances page, content current as of 14 May 2026, read 14 October 2026.

The agenda of the FDA's 23 and 24 July 2026 Pharmacy Compounding Advisory Committee meeting page lists seven substances that were considered for the 503A bulks list. They are BPC-157, KPV, TB-500, MOTs-C, emideltide, semax and epitalon. The page content is current as of 6 August 2026. We read it on 14 October 2026. The FDA says advisory committees make recommendations that are not binding. The meeting page we read has no vote result, so this page reports none.

Action against sellers is a separate track. An FDA warning letter of 24 August 2026 (letter 733652) says the seller marketed the products 'for laboratory, research, and analytical use'. It says the seller also marketed them as 'not intended for human or veterinary use'. But evidence from the seller's website shows the products are meant to be drugs for human use. The letter names nine products as unapproved new drugs. These include ones labelled 'GLP-1 Sema Research Peptide', 'GLP-2 Tirz Peptide', 'GLP-3 RT (Retatrutide) Research Peptide' and 'Tesamorelin Research Peptide'. Source: FDA, 24 August 2026. Retatrutide's status in Australia and the US covers the retatrutide detail.

Comparison

Twelve catalogue compounds compared against F2026L01327, the October 2026 Poisons Standard. Source reading: as-made text, 14 October 2026 (UTC). A class entry is a group heading that can cover more than one substance. GHK-Cu and tesamorelin are held: this page states no status for them. Later editions are not covered.

Comparison: Are peptides legal in Australia? Research peptide schedule status
CompoundEntry text in the instrumentSchedule and appendixClass-entry cautionDate read
BPC-157: a 15-amino-acid fragment of a peptide from gastric (stomach) juice (Sikirić et al., 1993)'# BPC-157.'Schedule 4; Appendix D, clause 5, item 5Named entry. Section 7 reaches derivatives and preparations.14 October 2026
CJC-1295: a lab-made analogue (modified copy) of growth-hormone-releasing hormone (Teichman et al., 2006)'# CJC-1295 (CAS No. 863288-34-0).'Schedule 4; Appendix D, clause 5, item 7Named entry with a CAS number. The instrument does not use the catalogue label 'No DAC'.14 October 2026
Ipamorelin: a lab-made peptide five amino acids long (Raun et al., 1998)'# IPAMORELIN.'Schedule 4; Appendix D, clause 5, item 25Named entry; section 7 applies as above.14 October 2026
TB-500: a peptide product ingredient named by the TGA (13 April 2026)'# TB-500.'Schedule 4; Appendix D, clause 5, item 38Named entry, separate from the entry for thymosin beta 4.14 October 2026
Tirzepatide: a lab-made peptide with a fatty acid attached (Coskun et al., 2018; Hammoud et al., 2024)'TIRZEPATIDE.'Schedule 4; Appendix L, clause 2, item 41 (warning statement number 67)Named entry with no # marker, so no Appendix D entry.14 October 2026
Semax: a seven-amino-acid peptide modelled on a fragment of the hormone ACTH (adrenocorticotropin, a body signal) (Dolotov et al., 2006)None found under the name 'semax'.No individual entry foundNot a statement that it is lawful or outside every group heading.14 October 2026
Selank: a synthetic (lab-made) analogue (modified copy) of the peptide tuftsin (Kolomin et al., 2011)None found under the name 'selank' or its variants.No individual entry foundNo group-heading conclusion is drawn for selank.14 October 2026
NAD+: nicotinamide adenine dinucleotide, a coenzyme (a helper molecule for enzymes), not a peptide (Covarrubias et al., 2021, a review article; [ChEBI, CHEBI:15846](https://www.ebi.ac.uk/chebi/CHEBI:15846))None found under either name.No individual entry foundWhether any group heading covers NAD+ is not decided here.14 October 2026
MOTS-c: a 16-amino-acid peptide encoded in mitochondrial DNA, the genetic instructions inside the energy-making parts of cells (Lee et al., 2015)None found under the name 'MOTS-c' or its variants.No individual entry foundWhether a group heading reaches MOTS-c is left open here.14 October 2026
Retatrutide: a lab-made peptide (Jastreboff et al., 2023)None found under the name or research codes.No individual entry foundNo conclusion is drawn on group headings for retatrutide.14 October 2026
GHK-Cu: the copper form of a peptide called GHK (catalogue record of this site)HELD. No entry text is quoted.HELD. No status is stated.HELD. This page states no status for GHK-Cu, in either direction.Held
Tesamorelin: a peptide (catalogue record of this site)HELD. No entry text is quoted.HELD. No status is stated.HELD. This page states no status for tesamorelin, in either direction.Held

FAQ

Is BPC-157 legal in Australia?

The October 2026 Poisons Standard lists BPC-157 by name in Schedule 4 and at item 5 of Appendix D, clause 5. We read the as-made text on 14 October 2026. Those are sorting labels. They are not a verdict on any person's situation. In its 13 April 2026 advisory, the TGA lists BPC-157 as one example of an unapproved peptide product. The BPC-157 research guide covers the compound itself.

Is CJC-1295 Schedule 4 in Australia?

Yes, by name. CJC-1295 has its own Schedule 4 entry, written '# CJC-1295 (CAS No. 863288-34-0).'. It also has an Appendix D, clause 5 entry at item 7. Both are in the October 2026 instrument, as-made text read on 14 October 2026. The entry names one CAS number. This page does not decide whether a given formulation falls under it.

Are ipamorelin and TB-500 Schedule 4 in Australia?

Yes, both have individual entries in F2026L01327, the October 2026 edition. We read the as-made text on 14 October 2026. Ipamorelin is '# IPAMORELIN.' with Appendix D item 25. TB-500 is '# TB-500.' with Appendix D item 38. Thymosin beta 4 has its own separate entries. Each entry is a sorting label. It decides nothing about any person's situation.

Does 'research use only' make peptides legal in Australia?

No. The TGA says a 'research use only' disclaimer does not make a product's supply lawful. Such disclaimers also do not change a product's regulatory status or permit importation. They do not remove duties about advertising or supply. Source: TGA advisory, 13 April 2026.

Is NAD+ a peptide?

No. NAD+ is nicotinamide adenine dinucleotide. It is a coenzyme with a nucleotide structure. It is not a chain of amino acids. Sources: Covarrubias et al., 2021, a review article, and ChEBI, CHEBI:15846. Our 14 October 2026 text search of the October 2026 instrument found no individual entry for it. This does not mean it is lawful.

Are peptides legal in Australia?

It depends on the substance, the product and the activity. The TGA says some peptide products are approved. It also says many products sold online are unapproved therapeutic goods. They may be unlawful to import, supply or advertise. The page was last updated on 23 September 2026. Named peptides also have Poisons Standard entries.

Can I legally import peptides into Australia?

Only under strict conditions. The TGA says a 'research use only' disclaimer does not permit importation. Unapproved products can enter under the Personal Importation Scheme only if every condition is met. Poorly labelled vials will not be released. Sources: TGA, 13 April and 7 May 2026. The import section above sums up some of the conditions and links to the TGA's full requirements.

Is it illegal to mail peptides?

Australia Post's guide lists poisons in the Commonwealth Standard for Uniform Scheduling of Drugs & Poisons as prohibited toxic substances. There is an exception for therapeutic drugs and medicines, ready for use. They can be carried under its Restricted Items List conditions. These include not causing a breach of any State, Territory or Commonwealth law. Source: 22 May 2024 edition, read 14 October 2026. The guide does not name peptides.

What peptides did the FDA ban?

The FDA pages we read publish no ban on a whole class. Its category 2 compounding list names GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 among peptides that may carry significant safety risks. The list is current as of 22 April 2026.

Are peptides legal in Perth?

It depends on the peptide and the activity. Perth follows Commonwealth rules plus Western Australia's Medicines and Poisons Regulations 2016. Regulation 6 of those Regulations classes substances in the current Poisons Standard schedules as poisons in the matching WA Schedule. This is version 00-u0-00. We read it on 14 October 2026.

Citations

10 sources
  1. Sikirić P et al. Journal of Physiology-Paris. 1993;87(5):313-327.
    doi:10.1016/0928-4257(93)90038-U

  2. Teichman SL et al. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
    doi:10.1210/jc.2005-1536

  3. Raun K et al. European Journal of Endocrinology. 1998;139(5):552-561.
    doi:10.1530/eje.0.1390552

  4. Coskun T et al. Molecular Metabolism. 2018;18:3-14.
    doi:10.1016/j.molmet.2018.09.009

  5. Dolotov OV et al. Brain Research. 2006;1117(1):54-60.
    doi:10.1016/j.brainres.2006.07.108

  6. Kolomin T et al. Regulatory Peptides. 2011;170(1-3):18-23.
    doi:10.1016/j.regpep.2011.05.001

  7. Covarrubias AJ et al. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
    doi:10.1038/s41580-020-00313-x

  8. Lee C et al. Cell Metabolism. 2015;21(3):443-454.
    doi:10.1016/j.cmet.2015.02.009

  9. Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972

  10. Hammoud R et al. JCI Insight. 2024 Dec 26;10(3):e174825.
    doi:10.1172/jci.insight.174825

Questions answered here

04
  1. What did the March 2026 PBAC decide on tirzepatide?The March 2026 PBAC recommendation for tirzepatide, with the dated official decision linked. A committee recommendation does not establish a listing date.Updated 2026-10-15
  2. What did the November 2025 PBAC decide on semaglutide?The November 2025 PBAC semaglutide recommendation for a defined cardiovascular disease and obesity population, linked to the official decision and its date.Updated 2026-10-15
  3. What is the status of the retatrutide TRIUMPH-OUTCOMES trial?NCT06383390: the dated ClinicalTrials.gov status of retatrutide TRIUMPH-OUTCOMES, its estimated completion and whether registry results are posted.Updated 2026-10-15
  4. What Schedule 4 and Appendix D mean for research peptidesWhat Schedule 4 and Appendix D, clause 5 of the October 2026 Poisons Standard mean, set side by side with the exact clause wording, read 1 October 2026.Updated 2026-10-04

Form Laboratories supplies research-use-only reference material. Everything in this hub is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease